ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

被引：0
|
作者：
Tsukamoto, K. [1 ]
Harriet S, W. [1 ,2 ,3 ]
Sandrine, J. [1 ,3 ]
Dyer, M. J. [1 ,2 ,3 ]
机构：
[1] Univ Leicester, Canc Studies, Leicester, Leics, England
[2] Univ Leicester, Mol & Cell Biol, Leicester, Leics, England
[3] Univ Leicester, Ernest Waudby & Helen Scott Haematol Res Inst, Leicester, Leics, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1372
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [21] Tyrosine Kinase Inhibitor Si409 Has In Vitro and In Vivo Anti-Tumor Activity Against Diffuse Large B-Cell Lymphoma
    Enrico Rango
    Salvatore Di Maria
    Claudio Zamperini
    Federica Poggialini
    Emmanuele Crespan
    Cecilia Perini
    Samantha Sabetta
    Simona Saponara
    Fabio Fusi
    Giovanni Maga
    Adriano Angelucci
    Eugenio Gaudio
    Francesco Berton
    Silvia Schenone
    Lorenzo Botta
    Elena Dreassi
    Maurizio Botta
    Pharmaceutical Chemistry Journal, 2023, 56 : 1616 - 1626
  • [22] BAY 2402234: Preclinical evaluation of a novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of diffuse large B-cell lymphoma (DLBCL)
    Eheim, Ashley
    Christian, Sven
    Meyer, Hanna
    Stoeckigt, Detlef
    Merz, Claudia
    Zimmermann, Katja
    Bauser, Marcus
    Haegebarth, Andrea
    Ferrara, Steven
    Sykes, David B.
    Scadden, David T.
    Gradl, Stefan
    Janzer, Andreas
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
    Yang, C.
    Lu, P.
    Lee, F. Y.
    Chadburn, A.
    Barrientos, J. C.
    Leonard, J. P.
    Ye, F.
    Zhang, D.
    Knowles, D. M.
    Wang, Y. L.
    LEUKEMIA, 2008, 22 (09) : 1755 - 1766
  • [24] Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
    C Yang
    P Lu
    F Y Lee
    A Chadburn
    J C Barrientos
    J P Leonard
    F Ye
    D Zhang
    D M Knowles
    Y L Wang
    Leukemia, 2008, 22 : 1755 - 1766
  • [25] Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation
    Gresely, Benet Pera
    Balaguer, Francisco de Asis
    Cardenas, Mariano Gonzalo
    Revuelta, Maria Victoria
    Vidal, Maria Nieves Calvo
    Marullo, Rossella
    Zamponi, Nahuel
    Rivera, Ildefonso Ismael Rodriguez
    Ai, Yong
    Glickman, Joseph Fraser
    Barasoain, Isabel
    Diaz, Fernando
    Melnick, Ari
    Xue, Fengtian
    Cerchietti, Leandro
    BLOOD, 2017, 130
  • [26] A phase II study of enzastaurin, a protein kinase C-β (PKCβ) inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma (DLBCL)
    Robertson, M
    Kahl, B
    Vose, J
    de Vos, S
    Laughlin, M
    Flynn, P
    Rowland, K
    Cruz, J
    Goldberg, S
    Darnstein, C
    Enas, N
    Neuberg, D
    Savage, K
    Thornton, D
    Slapak, C
    Shipp, M
    BLOOD, 2005, 106 (11) : 275A - 275A
  • [27] NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma
    Saturno, Grazia
    Modugno, Michele
    Orsini, Paolo
    Cervi, Giovanni
    Buffa, Laura
    Motto, Ilaria
    Avanzi, Nilla
    Montemartini, Marisa
    Gasparri, Fabio
    Texido, Gemma
    Galvani, Arturo
    Isacchi, Antonella
    CANCER RESEARCH, 2023, 83 (07)
  • [28] First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma
    Gibouin, Vincent Cabaud
    Durand, Manon
    Boudesco, Christophe
    Hermetet, Francois
    Nozickova, Kristyna
    Chassagne-Clement, Catherine
    Abdelwahed, Mayssa
    Klener, Pavel
    Garrido, Carmen
    Jego, Gaetan
    LEUKEMIA, 2024, 38 (08) : 1742 - 1750
  • [29] Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
    Kavita Bhalla
    Sausan Jaber
    Nanaji Nahid M.
    Karen Underwood
    Afshin Beheshti
    Ari Landon
    Binny Bhandary
    Paul Bastian
    Andrew M. Evens
    John Haley
    Brian Polster
    Ronald B. Gartenhaus
    Scientific Reports, 8
  • [30] Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
    Bhalla, Kavita
    Jaber, Sausan
    Nahid, Nanaji M.
    Underwood, Karen
    Beheshti, Afshin
    Landon, Ari
    Bhandary, Binny
    Bastain, Paul
    Evens, Andrew M.
    Haley, John
    Polster, Brian
    Gartenhaus, Ronald B.
    SCIENTIFIC REPORTS, 2018, 8
12345